Use of rituximab and risk of re-hospitalization for children with neuromyelitis optica spectrum disorder

Table 2 Proportion of subjects administered non-glucocorticoid treatment regimens during first hospitalization (n = 180)

Treatment	n, (%)
Plasma exchange (PLEX)^a	56 (31.1)
Rituximab^b	52 (28.9)
Intravenous immunoglobulin (IVIg)^c	33 (18.3)
Mycophenolate mofetil	23 (12.8)
Azathioprine	15 (8.3)
Cyclophosphamide	10 (5.6
Methotrexate	1 (0.6)

Legend. Subjects were able to contribute to more than one treatment regimen therefore total does not equal 100%
^aPLEX + rituximab (n = 20)
^bRituximab only, without any of the above listed non-glucocorticoid agent (n = 23)
^cIVIg + rituximab (n = 8)

ISSN: 2056-6115